Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer

Cisplatin-epirubicin-paclitaxel used to treat operable breast cancer

"The present study aimed to define the antitumor activity of 8 PET weekly cycles with granulocyte colony-stimulating factor (G-CSF) support in patients with large operable breast cancer. Operable breast cancer (T2-3 N0-1; T>3 cm) patients received 8 preoperative weekly cycles of cisplatin 30 mg/m², epirubicin 50 mg/m² and paclitaxel 120 mg/m², with G-CSF (5 mcg/kg, days 3-5) support. Sixty-three patients (T2/T3=30/33; N0/N+=8/55) were enrolled," scientists writing in the journal...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications